Puma Biotechnology Stock Price, News & Analysis (NASDAQ:PBYI)

$105.50 2.35 (2.28 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$103.15
Today's Range$102.35 - $106.35
52-Week Range$28.35 - $136.90
Volume723,339 shs
Average Volume1.12 million shs
Market Capitalization$3.96 billion
P/E RatioN/A
Dividend YieldN/A

About Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:PBYI
  • CUSIP: N/A
  • Web: www.pumabiotechnology.com
  • Current Ratio: 1.23%
  • Quick Ratio: 1.23%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $2.11 per share
  • Price / Book: 50.00
  • Trailing EPS: ($8.19)
  • Net Income: ($276,010,000.00)
  • Return on Equity: -208.58%
  • Return on Assets: -145.91%
  • Employees: 160
  • Outstanding Shares: 37,530,000
Frequently Asked Questions for Puma Biotechnology (NASDAQ:PBYI)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) announced its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.50) by $0.43. The biopharmaceutical company had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company earned ($1.11) earnings per share. View Puma Biotechnology's Earnings History.

When will Puma Biotechnology make its next earnings announcement?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Puma Biotechnology.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

9 analysts have issued 1-year target prices for Puma Biotechnology's shares. Their predictions range from $92.00 to $164.00. On average, they anticipate Puma Biotechnology's stock price to reach $130.67 in the next year. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:

  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer (Age 47)
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer (Age 69)
  • Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer (Age 59)
  • Steven Lo, Chief Commercial Officer (Age 50)
  • Jay M. Moyes, Independent Director (Age 63)
  • Adrian M Senderowicz, Independent Director (Age 53)
  • Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
  • Frank E. Zavrl, Independent Director (Age 51)

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (6.72%), Janus Henderson Group PLC (5.04%), Perceptive Advisors LLC (2.46%), Point72 Asset Management L.P. (1.28%), Emerald Advisers Inc. PA (0.99%) and Schroder Investment Management Group (0.93%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Canada Pension Plan Investment Board, C WorldWide Group Holding A S, Neuberger Berman Group LLC, California State Teachers Retirement System, Cornerstone Capital Management Holdings LLC., Stifel Financial Corp and Principal Financial Group Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Insider Buying and Selling for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, Nicholas Investment Partners LP, Emerald Advisers Inc. PA, Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Dimensional Fund Advisors LP and Sanctuary Wealth Advisors LLC. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of Puma Biotechnology stock can currently be purchased for approximately $105.50.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $3.96 billion. The biopharmaceutical company earns ($276,010,000.00) in net income (profit) each year or ($8.19) on an earnings per share basis. Puma Biotechnology employs 160 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 Wilshire Blvd Ste 2150, LOS ANGELES, CA 90024-4106, United States. The biopharmaceutical company can be reached via phone at +1-424-2486500 or via email at [email protected]

MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Puma Biotechnology (NASDAQ:PBYI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $130.67 (23.85% upside)
Consensus Price Target History for Puma Biotechnology (NASDAQ:PBYI)
Price Target History for Puma Biotechnology (NASDAQ:PBYI)
Analysts' Ratings History for Puma Biotechnology (NASDAQ:PBYI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Credit Suisse GroupBoost Price TargetOutperform$136.00 -> $142.00N/AView Rating Details
11/10/2017Barclays PLCReiterated RatingBuy$103.00 -> $122.00N/AView Rating Details
11/10/2017Citigroup Inc.Boost Price TargetBuy -> Buy$156.00 -> $164.00N/AView Rating Details
11/10/2017Royal Bank Of CanadaLower Price TargetSector Perform$108.00 -> $92.00N/AView Rating Details
10/27/2017Leerink SwannBoost Price TargetPositive -> Outperform$140.00N/AView Rating Details
10/9/2017Bank of America CorporationReiterated RatingBuy$117.00 -> $135.00N/AView Rating Details
10/4/2017J P Morgan Chase & CoReiterated RatingBuy$131.00HighView Rating Details
10/2/2017Stifel NicolausBoost Price TargetBuy$110.00 -> $130.00LowView Rating Details
7/22/2017Cowen and CompanyReiterated RatingOutperform$91.00 -> $120.00MediumView Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 11/17/2015 forward)


Earnings History for Puma Biotechnology (NASDAQ:PBYI)
Earnings by Quarter for Puma Biotechnology (NASDAQ:PBYI)
Earnings History by Quarter for Puma Biotechnology (NASDAQ PBYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($2.50)($2.07)$3.78 million$6.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Puma Biotechnology (NASDAQ:PBYI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($2.03)($2.03)($2.03)
Q3 20171($2.20)($2.20)($2.20)
Q4 20171($1.96)($1.96)($1.96)
(Data provided by Zacks Investment Research)


Dividend History for Puma Biotechnology (NASDAQ:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puma Biotechnology (NASDAQ PBYI)
Insider Ownership Percentage: 21.10%
Institutional Ownership Percentage: 95.41%
Insider Trades by Quarter for Puma Biotechnology (NASDAQ:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)
Insider Trades by Quarter for Puma Biotechnology (NASDAQ PBYI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2017Richard Paul BryceSVPSell15,000$120.00$1,800,000.00View SEC Filing  
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.00View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.75View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.04View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.00View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Puma Biotechnology (NASDAQ:PBYI)
Latest Headlines for Puma Biotechnology (NASDAQ PBYI)

Social Media



Puma Biotechnology (NASDAQ PBYI) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.